Clinical Trial Update: Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update assessing safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Sars Pneumonia

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Beneficência Portuguesa de São Paulo | Conditions: COVID, SARS Pneumonia | Phase 3 | Status: TERMINATED